Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Quantum Biopharma Ltd (QNTM)

Quantum Biopharma Ltd (QNTM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,192
  • Shares Outstanding, K 3,817
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,180 K
  • EBIT $ -15 M
  • EBITDA $ -14 M
  • 60-Month Beta 0.13
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-2.89
  • Growth Rate Est. (year over year) +34,667.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.07 +92.27%
on 03/11/26
6.47 -38.49%
on 03/30/26
+0.38 (+10.56%)
since 03/02/26
3-Month
2.07 +92.27%
on 03/11/26
7.65 -47.97%
on 01/07/26
-3.03 (-43.22%)
since 01/02/26
52-Week
2.07 +92.27%
on 03/11/26
38.25 -89.59%
on 06/20/25
-4.06 (-50.50%)
since 04/02/25

Most Recent Stories

More News
Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied

TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“ Quantum BioPharma ” or the “ Company ”), a biopharmaceutical company dedicated to...

QNTM : 3.98 (-9.75%)
QNTM.CN : 5.6000 (-9.09%)
Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis

TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“ Quantum BioPharma ” or the “ Company ”), a biopharmaceutical company dedicated to...

QNTM : 3.98 (-9.75%)
QNTM.CN : 5.6000 (-9.09%)
Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis

TORONTO, March 30, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“ Quantum BioPharma ” or the “ Company ”), a biopharmaceutical company dedicated to...

QNTM : 3.98 (-9.75%)
QNTM.CN : 5.6000 (-9.09%)
Quantum Biopharma Provides Corporate Update

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, March 27, 2026...

QNTM : 3.98 (-9.75%)
QNTM.CN : 5.6000 (-9.09%)
Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ Status

Multiple Sclerosis Drug Candidate Lucid-21-302 Phase 1 Trial with Toxicology Studies Complete, and unbuzzd ™ Clinical Trial Published in Peer-Reviewed Journal TORONTO, March 27, 2026 (GLOBE...

QNTM : 3.98 (-9.75%)
QNTM.CN : 5.6000 (-9.09%)
Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis

TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“ Quantum BioPharma ” or the “ Company ”), a biopharmaceutical company dedicated to...

QNTM : 3.98 (-9.75%)
QNTM.CN : 5.6000 (-9.09%)
Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd

TORONTO, March 23, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“ Quantum BioPharma ” or the “ Company ”), "Company"), a biopharmaceutical company dedicated...

QNTM : 3.98 (-9.75%)
QNTM.CN : 5.6000 (-9.09%)
Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, March 20, 2026...

QNTM : 3.98 (-9.75%)
QNTM.CN : 5.6000 (-9.09%)
Quantum BioPharma Provides Corporate Update

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, March 11, 2026...

QNTM : 3.98 (-9.75%)
QNTM.CN : 5.6000 (-9.09%)
Quantum BioPharma Provides Corporate Update

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.   TORONTO, March 10,...

QNTM : 3.98 (-9.75%)
QNTM.CN : 5.6000 (-9.09%)

Business Summary

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Quantum BioPharma,...

See More

Key Turning Points

3rd Resistance Point 5.16
2nd Resistance Point 4.88
1st Resistance Point 4.43
Last Price 3.98
1st Support Level 3.70
2nd Support Level 3.42
3rd Support Level 2.97

See More

52-Week High 38.25
Fibonacci 61.8% 24.43
Fibonacci 50% 20.16
Fibonacci 38.2% 15.89
Last Price 3.98
52-Week Low 2.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.